JP5033115B2 - Novel pharmaceutical composition and processed food for treating or preventing dry eye - Google Patents
Novel pharmaceutical composition and processed food for treating or preventing dry eye Download PDFInfo
- Publication number
- JP5033115B2 JP5033115B2 JP2008318445A JP2008318445A JP5033115B2 JP 5033115 B2 JP5033115 B2 JP 5033115B2 JP 2008318445 A JP2008318445 A JP 2008318445A JP 2008318445 A JP2008318445 A JP 2008318445A JP 5033115 B2 JP5033115 B2 JP 5033115B2
- Authority
- JP
- Japan
- Prior art keywords
- eye
- dry eye
- lactoferrin
- dry
- eyes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 208000003556 Dry Eye Syndromes Diseases 0.000 title claims description 43
- 206010013774 Dry eye Diseases 0.000 title claims description 43
- 235000021067 refined food Nutrition 0.000 title description 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 102000010445 Lactoferrin Human genes 0.000 claims description 27
- 108010063045 Lactoferrin Proteins 0.000 claims description 27
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 claims description 27
- 229940078795 lactoferrin Drugs 0.000 claims description 27
- 235000021242 lactoferrin Nutrition 0.000 claims description 27
- 238000002360 preparation method Methods 0.000 claims description 9
- 239000004480 active ingredient Substances 0.000 claims description 2
- 230000002650 habitual effect Effects 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 208000022873 Ocular disease Diseases 0.000 claims 1
- 210000001508 eye Anatomy 0.000 description 16
- 235000013336 milk Nutrition 0.000 description 11
- 239000008267 milk Substances 0.000 description 11
- 210000004080 milk Anatomy 0.000 description 11
- 239000003889 eye drop Substances 0.000 description 10
- 229940012356 eye drops Drugs 0.000 description 10
- 230000004304 visual acuity Effects 0.000 description 9
- 239000003814 drug Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 210000003296 saliva Anatomy 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000002702 enteric coating Substances 0.000 description 5
- 238000009505 enteric coating Methods 0.000 description 5
- 210000004561 lacrimal apparatus Anatomy 0.000 description 5
- 206010019233 Headaches Diseases 0.000 description 4
- 208000021386 Sjogren Syndrome Diseases 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 230000005784 autoimmunity Effects 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000004438 eyesight Effects 0.000 description 4
- 231100000869 headache Toxicity 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 3
- 206010052428 Wound Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 239000000607 artificial tear Substances 0.000 description 3
- 208000003464 asthenopia Diseases 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 208000027932 Collagen disease Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010015958 Eye pain Diseases 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 229920002494 Zein Polymers 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 210000000795 conjunctiva Anatomy 0.000 description 2
- 210000004087 cornea Anatomy 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 208000030533 eye disease Diseases 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 230000006058 immune tolerance Effects 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 210000003079 salivary gland Anatomy 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 229940093612 zein Drugs 0.000 description 2
- 239000005019 zein Substances 0.000 description 2
- ZSTLCHCDLIUXJE-ZGBAEQJLSA-N (2S,5S)-2-methylspiro[1,3-oxathiolane-5,3'-1-azabicyclo[2.2.2]octane] hydrate dihydrochloride Chemical compound O.Cl.Cl.C1S[C@@H](C)O[C@@]21C(CC1)CCN1C2.C1S[C@@H](C)O[C@@]21C(CC1)CCN1C2 ZSTLCHCDLIUXJE-ZGBAEQJLSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- KYLIZBIRMBGUOP-UHFFFAOYSA-N Anetholtrithion Chemical compound C1=CC(OC)=CC=C1C1=CC(=S)SS1 KYLIZBIRMBGUOP-UHFFFAOYSA-N 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 235000002673 Dioscorea communis Nutrition 0.000 description 1
- 241000544230 Dioscorea communis Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000798114 Homo sapiens Lactotransferrin Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241001469893 Oxyzygonectes dovii Species 0.000 description 1
- QHZLMUACJMDIAE-UHFFFAOYSA-N Palmitic acid monoglyceride Natural products CCCCCCCCCCCCCCCC(=O)OCC(O)CO QHZLMUACJMDIAE-UHFFFAOYSA-N 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 208000035753 Periorbital contusion Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 241000231739 Rutilus rutilus Species 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- WMGSQTMJHBYJMQ-UHFFFAOYSA-N aluminum;magnesium;silicate Chemical compound [Mg+2].[Al+3].[O-][Si]([O-])([O-])[O-] WMGSQTMJHBYJMQ-UHFFFAOYSA-N 0.000 description 1
- 229960005238 anethole trithione Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000004397 blinking Effects 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 229960002745 cevimeline hydrochloride Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 231100000040 eye damage Toxicity 0.000 description 1
- 239000003885 eye ointment Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 102000050459 human LTF Human genes 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 208000000122 hyperventilation Diseases 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000003750 lower gastrointestinal tract Anatomy 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229940117841 methacrylic acid copolymer Drugs 0.000 description 1
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 239000011812 mixed powder Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000004379 myopia Effects 0.000 description 1
- 208000001491 myopia Diseases 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- -1 potato starch Chemical class 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000011164 primary particle Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000002893 slag Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
Description
本発明はドライアイ並びにコンタクトレンズによる眼障害等の難治性眼疾患の治療・予防に関する。 The present invention relates to treatment / prevention of intractable eye diseases such as eye damage caused by dry eye and contact lenses.
近年、テレビ、パソコンなどに囲まれ眼を酷使する機会が多く、目が疲れやすい、あるいは何となく目に不快感を感ずる人が増えている。疲れ眼などのように眼に不快感があると、仕事だけでなく、日常生活でもたいへん不便を来すことが多い。このような疲れ眼などの原因として最近注目を集めているのが眼の乾き、ドライアイである。ドライアイはわが国で800万人以上の患者が悩まされていると推定されているが、病気としての認識度の低い疾患である。 In recent years, there are many opportunities to overuse the eyes surrounded by televisions, personal computers, etc., and the number of people who tend to get tired easily or feel some discomfort in the eyes is increasing. Discomfort in the eyes, such as tired eyes, is often very inconvenient not only in work but also in daily life. Recently, dry eyes have been attracting attention as a cause of such fatigue eyes. Although dry eye is estimated to affect more than 8 million patients in Japan, it is a disease with low recognition as a disease.
眼が乾くために不快な症状が現れるドライアイは、涙の減少あるいは質的変化により眼の表面に障害を生じる疾患である。涙が不足していると、眼は乾いて傷つきやすい状態になる。重症になると眼の表面に無数の傷が付いている場合もある。軽い症状はやがて治癒することもあるが、症状が重かったり、いつまでも続くようであれば、眼の表面が傷ついている可能性がある。このような場合、傷から病原菌が感染したり、傷が深くなって視力の低下が懸念されるので、医療機関で診察を受ける必要がある。 Dry eye, in which unpleasant symptoms appear due to dryness of the eyes, is a disease that causes damage to the surface of the eye due to decreased tears or qualitative changes. When tears are deficient, the eyes become dry and vulnerable. In severe cases, the surface of the eye may have countless scratches. Mild symptoms may heal over time, but if the symptoms are severe or persist forever, the surface of the eye may be damaged. In such a case, since pathogens are infected from the wound, or the wound becomes deep and there is a concern about a decrease in visual acuity, it is necessary to consult a medical institution.
目は、「みる」ことにより多くの情報を手にいれるのに必要な重要器官である。涙が少なくなりドライアイが起こると、さまざまな症状があらわれ、快適にものをみることができなくなる。さらにひどくなると、常習性角膜上皮剥離という眼病が起こる。とくに、季節的な「乾燥+オフィスでの暖房による乾燥」、「コンピューター作業によるストレスの蓄積」、「熱中してディスプレイを凝視することによる“マバタキ”の減少」、「眼の緊張をとるための休息もない場合」、眼を酷使し、涙が減って“マバタキ”しても、眼球を涙で潤すことができなくなる。普通ドライアイにより失明することはないが、重症になると眼の表面に無数の傷が入り角膜や結膜に障害が起こって、視力低下、眼が開けられない事態に陥ることも珍しくない。コンタクトレンズを使用する場合にも、ドライアイが頻発し最終的には装着できなくなることがある。 The eye is an important organ that is necessary to obtain a lot of information by “seeing” it. When tears decrease and dry eyes occur, various symptoms appear, making it difficult to see things comfortably. When it gets worse, an eye disease called addictive corneal epithelial detachment occurs. In particular, seasonal “drying + drying by heating in the office”, “accumulation of stress due to computer work”, “reduction of“ Mabataki ”by staring at the display with heat,” “for eye strain” If there is no rest, even if the eyes are overworked and tears decrease and “mabataki” occurs, the eyes cannot be moistened with tears. It is not uncommon for dry eyes to cause blindness, but if it becomes severe, countless wounds may occur on the surface of the eye, causing damage to the cornea and conjunctiva, resulting in a situation where vision is reduced and the eye cannot be opened. Even when contact lenses are used, dry eye may occur frequently and eventually cannot be worn.
また、全身の病気の一症状としてドライアイが起こることがある。その代表的なものとして、シェーグレン症候群がある。これは、涙を分泌している涙腺が自己免疫により徐々に破壊されて涙の分泌量が減少する病気で、涙腺だけでなく唾液腺も破壊されるので唾液の分泌が低下し、乾燥した食品を食べるとき水分が必要になる。そのほか、ドライアイは慢性関節リウマチ、膠原病及び糖尿病に合併することがある。一方、精神安定剤やその他のさまざまな薬の副作用によって涙の量が減ることもある。また、目薬の種類や点眼回数によってドライアイが起こることもあるので、新しい薬をのみはじめたり、新しい目薬をさしはじめてから、目が乾く・疲れるなどの症状がでたときには、医師に相談する必要がある。 Also, dry eye may occur as a symptom of systemic illness. A typical example is Sjogren's syndrome. This is a disease in which the lacrimal glands that secrete tears are gradually destroyed by autoimmunity and the amount of tears secreted decreases, and not only the lacrimal glands but also the salivary glands are destroyed. When you eat, you need water. In addition, dry eye may be associated with rheumatoid arthritis, collagen disease and diabetes. On the other hand, side effects of tranquilizers and various other drugs can reduce tear volume. Also, since dry eye may occur depending on the type of eye drops and the number of eye drops, consult with a doctor if symptoms such as dry eyes or tired eyes appear after starting new drugs or starting new eye drops. There is a need.
一般的に、軽いドライアイの場合は、少なくなった涙を補充する目的で人工涙液とよばれる涙とよく似た成分の目薬を必要に応じて使用する。この場合も、さまざまな種類の人工涙液があり、患者にもっとも適した人口涙液をさがす必要がある。また、乾燥感が強く点眼回数が増える場合には、防腐剤の入っていない点眼薬を選択するなどの配慮も必要である。さらに、黒目(角膜)や白目(結膜)の表面に傷があり、まばたきをすると異和感・痛みがあるといった場合には、点眼剤とともに潤滑剤として眼軟膏を使う場合もある。そのような治療をしても効果のない重症のドライアイの場合には、残っている本人の涙を少しでも長い時間、目の表面に滞留させておくため、涙の排出口を閉じてしまう治療を行う。その他の治療法として、涙の乾きを抑えるために特別に開発された眼鏡をかけるという方法もある。 In general, in the case of light dry eyes, eye drops having a component similar to tears, which is called artificial tears, are used as needed for the purpose of replenishing less tears. Again, there are various types of artificial tears, and it is necessary to look for artificial tears that are most suitable for the patient. In addition, when the feeling of dryness is strong and the number of eye drops increases, it is also necessary to consider eye drops that do not contain preservatives. Furthermore, when there are scratches on the surface of the black eye (cornea) or white eye (conjunctiva), and there is a feeling of strangeness or pain when blinking, an eye ointment may be used as a lubricant together with eye drops. In the case of severe dry eye that is not effective even after such treatment, the tears are closed because the remaining tears remain on the surface of the eyes for as long as possible. Give treatment. Another treatment is to wear glasses specially developed to prevent dry tears.
シェーグレン症候群によるドライマウスの内服治療薬としては塩酸セビメリンが2002年に認可され、医療機関で使われ始めたが、ドライアイへの適用拡大は成功していない。胆汁分泌を促進する経口剤であるアネトールトリチオンも唾液分泌促進作用もあることから、シェーグレン症候群に伴う唾液分泌減少の改善にも使用される。しかし、これらの薬物はドライマウス並びにドライアイに共通した病因である唾液腺並びに涙腺に対する自己免疫を改善する方向には作用しない。つまり、現状では内服ないし注射で安全にドライアイに改善できる薬物は存在しない。従って、高度に安全でドライアイを改善できる医薬品ないし加工食品は、長年探し求められていたのである。 Cevimeline hydrochloride was approved in 2002 as an internal medicine for dry mice with Sjögren's syndrome, and began to be used in medical institutions, but its application to dry eyes has not been successful. Anethole trithione, which is an oral preparation that promotes bile secretion, also has a salivary secretion promoting action, so it is also used to improve salivary secretion reduction associated with Sjogren's syndrome. However, these drugs do not act to improve autoimmunity against salivary glands and lacrimal glands, which are common etiologies in dry mice and dry eyes. In other words, at present, there is no drug that can be safely improved to dry eye by internal use or injection. Therefore, pharmaceuticals or processed foods that are highly safe and can improve dry eye have been sought for many years.
安全かつ生活の質を低下させることなくドライアイを改善できる物質を発見することが、この発明が解決しようとする課題である。上述したようにドライアイは、いろいろの原因で起こる。涙を産生する涙腺を破壊する自己免疫を発症するシェーグレン症候群がドライアイを起こすことが知られているが、その他にも慢性関節リューマチ、膠原病、II型糖尿病もしばしばドライアイを随伴する。また、コンピューター及びテレビのディスプレイ、コンタクトレンズの脱着もドライアイを誘発すると言われるが、因果関係は明確ではない。いずれにせよ、ドライアイは生命を危険に陥れるような病気ではないので、ドライアイの治療薬ないし治療用食品はまったく生活の質を低下することなく病態を改善できる物質である必要がある。これは甚だ難しい課題である。 It is a problem to be solved by the present invention to find a substance that can improve dry eye safely and without reducing the quality of life. As described above, dry eye occurs for various reasons. Sjogren's syndrome, which develops autoimmunity that destroys the lacrimal glands that produce tears, is known to cause dry eye, but rheumatoid arthritis, collagen disease, and type II diabetes often accompany dry eye. In addition, it is said that the attachment and detachment of computer and television displays and contact lenses also induce dry eyes, but the causal relationship is not clear. In any case, since dry eye is not a life-threatening disease, it is necessary that the therapeutic or food for dry eye be a substance that can improve the pathology without degrading the quality of life at all. This is a very difficult task.
本発明者らは課題を解決するため試行錯誤を繰り返したところ、ラクトフェリンが臨床的にドライアイを改善することを発見し本発明を完成するに至った。本発明に使用されたラクトフェリンは、牛乳から抽出されたラクトフェリン、遺伝子工学的に調製された遺伝子組み換えヒトラクトフェリンを含む。本発明のヒントとなったのは、牛乳ラクトフェリン300mgを一日一回、健常者に1週間経口投与すると、唾液のpHを有意に上昇させる効果がある実験である。唾液のpHは唾液の産生量と比例するので、この事実はラクトフェリンが健常者の唾液産生を増加させたことを意味する。この試験における被験者は健常者なので、牛乳ラクトフェリンがドライマウスに悩む病者の唾液産生を増加させることを意味しない。しかし、牛乳ラクトフェリンを経口投与すると、自己免疫と考えられるアレルギー性鼻炎、慢性気管支喘息、慢性関節リューマチ、蕁麻疹などを改善するので、経口投与した牛乳ラクトフェリンは自己免疫に対する免疫的寛容を導入し、慢性炎症を改善する作用があると考えられる。つまり、健常者に対する唾液産生増大効果と免疫的寛容を導入する作用の二つから、ラクトフェリンは涙腺にも作用して涙の産生を増大させるであろうと推定した。 The present inventors have repeated trial and error in order to solve the problem, and have found that lactoferrin clinically improves dry eye and have completed the present invention. The lactoferrin used in the present invention includes lactoferrin extracted from milk and recombinant human lactoferrin prepared by genetic engineering. The hint of the present invention is an experiment having an effect of significantly increasing the pH of saliva when 300 mg of milk lactoferrin is orally administered to a healthy person once a day for one week. Since saliva pH is proportional to the amount of saliva produced, this fact means that lactoferrin increased saliva production in healthy individuals. Since the test subjects in this study are healthy, it does not mean that milk lactoferrin increases saliva production in sick people suffering from dry mice. However, oral administration of milk lactoferrin improves allergic rhinitis, chronic bronchial asthma, rheumatoid arthritis, urticaria, etc. that are considered to be autoimmune, so milk lactoferrin administered orally introduces immune tolerance to autoimmunity, It is thought to have an effect of improving chronic inflammation. In other words, it was estimated that lactoferrin would also increase the production of tears by acting on the lacrimal gland from the effect of increasing saliva production and the introduction of immune tolerance for healthy individuals.
ドライアイには適切な実験動物の病態モデルが存在しない。従って、直接にヒトに投与して有用性を判定する人体実験に依存せざるを得ない。そこで中程度から重症のドライアイに悩むボランティアー5人に牛乳ラクトフェリンを一日あたり2〜6錠、毎日2〜3回1カ月経口投与し、ドライアイに及ぼす効果を検討した。使用したのは牛乳ラクトフェリンを1錠中に100mg含有する腸溶性製剤である。その結果、実施例に示すように早いもので内服を始めて3日後、遅くとも7日後にドライアイが著しく改善された。また、視力が回復したボランティアーが3名あったが、ドライアイが改善されて頻繁にマバタキする必要がなくなったので、一カ所を長時間見つめることができるようになったための現象と思われる。 There is no suitable experimental animal pathology model for dry eye. Therefore, it is necessary to rely on human experiments to determine the usefulness by directly administering to humans. Therefore, 5 volunteers suffering from moderate to severe dry eye were orally administered with 2-6 tablets of milk lactoferrin per day, 2-3 times daily for 1 month, and the effect on dry eye was examined. An enteric preparation containing 100 mg of milk lactoferrin in one tablet was used. As a result, as shown in the examples, dry eye was remarkably improved 3 days after the start of oral administration and 7 days at the latest. In addition, there were three volunteers who recovered their vision, but it seems that this is because it became possible to stare at one place for a long time because dry eye was improved and it was no longer necessary to do the mabataki frequently.
本発明の実施態様は、経口剤が主要なものであるが、その他にトローチなどの剤型で実用に供することができる。ラクトフェリンは分子量が8万ダルトン前後の高分子であり、比較的不安定なこと、胃内では酸性条件下でペプシンにより容易に分解されるので製剤化にあたって注意が必要である。例えば、経口剤はラクトフェリン顆粒ないしは錠剤の表面を胃では溶解せず、腸に流入して溶解する腸溶性の皮膜で被覆した製剤が望ましい。より詳細には、次のようなものである。牛乳由来ラクトフェリン凍結乾燥粉末は、かさ比重が非常に小さく、直接錠剤に打錠することは困難である。また、水分と高温で不安定なので、乾燥状態で製剤化することが望ましい。したがって、ラクトフェリンと賦形剤、結合剤、崩壊剤を混合し、混合物をスラグマシンで強圧成型し薄い大きな平たい円盤をつくり・それを砕いて箭過し、一定の大きさの穎粒をそろえる。この穎粒を腸溶性皮膜で覆い、一定量をハードカプセルに充填して製品化することができる。錠剤として製品化する場合には、穎粒に滑沢剤を加えて打錠し、錠剤を腸溶性皮膜で覆って製品化することができる。 Embodiments of the present invention is the oral agent is of major, it can be put into practical use in the dosage form such as other bets Roach. Lactoferrin is a polymer having a molecular weight of around 80,000 daltons, and is relatively unstable. In the stomach, lactoferrin is easily degraded by pepsin under acidic conditions. For example, an oral preparation is preferably a preparation in which the surface of a lactoferrin granule or tablet is coated with an enteric film that does not dissolve in the stomach but flows into the intestine and dissolves. More specifically, it is as follows. Milk-derived lactoferrin lyophilized powder has a very low bulk specific gravity and is difficult to be directly compressed into tablets. Moreover, since it is unstable at moisture and high temperature, it is desirable to formulate it in a dry state. Therefore, lactoferrin is mixed with excipients, binders and disintegrants, and the mixture is pressure-molded with a slag machine to form a thin large flat disk, which is crushed and filtered to prepare grains of a certain size. The granules can be covered with an enteric coating, and a certain amount can be filled into a hard capsule to produce a product. In the case of commercialization as a tablet, a lubricant can be added to the granule for tableting, and the tablet can be covered with an enteric coating for commercialization.
本発明の腸溶性製剤を製造する際に用いる賦形剤としては、乳糖、庶糖、マルチトール、グルコースなどの単糖ないし二糖類、コーンスターチ、ポテトスターチのような澱粉類、結晶セルローズ、無機物としては軽質シリカゲル、合成珪酸アルミニウム、メタ珪酸アルミン酸マグネシウム、リン酸水素カルシウムなどがある。また、結合剤としては澱粉類、カルボキシメチルセルロース(CMC)、ヒドロキシプロピルセルローズ(HPC)、カルボキシメチルセルロース−ナトリウム塩、ポリビニルピロリドン等がある。また、下部消化管でもとの一次粒子にまで崩壊させることを目的として用いる崩壊剤としては、澱粉、カルボキシメチルセルロース−ナトリウム塩、カルボキシメチルセルロース−カルシウム塩、クロスカルメロースナトリウム、カルボキシメチルスターチナトリウムなどがある。錠剤ならびに穎粒を腸溶性に被覆するための皮膜剤としては、PH5〜6で溶解するヒドロキシプロピルメチルセルローズフタレート、カルボキシメチルエチルセルロース、酢酸フタル酸セルローズ、メタクリル酸コポリマー、トウモロコシ穀粒に含まれるツェインや、アルカリ性領域で溶解するシェラックなどがある。 Examples of excipients used in producing the enteric preparation of the present invention include lactose, sucrose, maltitol, glucose and other monosaccharides or disaccharides, corn starch, starch such as potato starch, crystalline cellulose, and inorganic substances. Examples include light silica gel, synthetic aluminum silicate, magnesium aluminate metasilicate, and calcium hydrogen phosphate. Examples of the binder include starches, carboxymethyl cellulose (CMC), hydroxypropyl cellulose (HPC), carboxymethyl cellulose-sodium salt, and polyvinylpyrrolidone. Examples of disintegrants used for the purpose of disintegrating them into primary particles in the lower gastrointestinal tract include starch, carboxymethylcellulose-sodium salt, carboxymethylcellulose-calcium salt, croscarmellose sodium, and carboxymethyl starch sodium. . Examples of coating agents for enteric coating of tablets and grains include hydroxypropylmethylcellulose phthalate, carboxymethylethylcellulose, cellulose acetate phthalate, methacrylic acid copolymer, zein contained in corn kernel , and the like shellac dissolves in alkaline region.
本発明の製剤は、一般的には、活性成分として1日あたり、約0.1mg〜約100,000mg、好ましくは約1mg〜約50,000mg、より好ましくは約10mg〜約10,000mgを一度に又は分割して、本発明の製剤による治療または状態の改善が必要とされている患者に投与することができる。投与量及び投与剤型は、個別に、投与される患者の年齢、体重、病態および投与目的に応じて定めることができる。 The formulations of the present invention will generally contain from about 0.1 mg to about 100,000 mg, preferably from about 1 mg to about 50,000 mg, more preferably from about 10 mg to about 10,000 mg once a day as the active ingredient. Or in divided portions can be administered to patients in need of treatment or improvement of condition with the formulations of the invention. The dosage and dosage form can be individually determined according to the age, weight, pathological condition and purpose of administration of the patient to be administered.
実施例1:
牛乳から抽出したラクトフェリン原末(蛋白質として純度97%、タンパク質中のラクトフェリン含有93%)30kgに微結晶セルローズ(商品名;アビセル)57.5kg、デキストリン2.4kg、ステアリン酸マグネシウム0.1kgをミキサーで粉砕し、100メッシュを通過する粉末とした。この混合粉末を打錠機により打錠して直径9mm、重量の錠剤とした。次ぎにコーティング機に錠剤をいれ、ツェイン9%、パルミチン酸モノグリセライド1%、エタノール75%、純水15%よりなる腸溶性コーティング液を噴霧し、対錠剤重量比で10%の腸溶性コーティングを施して製品とした。
Example 1:
Mixer of lactoferrin bulk powder extracted from milk (purity 97% as protein, 93% lactoferrin in protein) 57.5 kg microcrystalline cellulose (trade name: Avicel), 2.4 kg dextrin, 0.1 kg magnesium stearate To obtain a powder passing through 100 mesh. This mixed powder was compressed into tablets with a diameter of 9 mm and a weight by a tableting machine. Next, the tablets are put in a coating machine, sprayed with an enteric coating solution consisting of 9% zein, 1% palmitic acid monoglyceride, 75% ethanol and 15% pure water, and 10% enteric coating is applied to the tablet by weight. Product.
実施例2:
48才女性;近眼のために十代からコンタクトレンズを装着していた。しかし、35才のとき眼が痛いので眼科医の診断を受けたところ、ドライアイによる常習性角膜上皮剥離と診断された。それ以来、眼の痛みのため点眼剤が手放せなくなった。2003年3月19日から実施例1で調製した牛乳ラクトフェリンを100mg含有する腸溶製剤を一日2個朝夕に分けて内服したところ、3日目に眼の痛みが消失し、それに伴って点眼薬が不要になった。さらにラクトフェリン腸溶製剤の内服を続け2週間目に眼科医の診断を受けたところ、常習性角膜上皮剥離が治癒したと云われた。また、30年以上も装着できなかったコンタクトレンズを再び使用できるようになった。
Example 2:
48-year-old woman: Wearing contact lenses for teenagers since her teenage years. However, when I was 35 years old, my eyes hurt, so I was diagnosed with addictive corneal epithelial detachment due to dry eye. Since then, eye drops cannot be released due to eye pain. When the enteric preparation containing 100 mg of milk lactoferrin prepared in Example 1 from March 19, 2003 was divided into two morning and evening doses, eye pain disappeared on the third day, and instillation was accompanied accordingly. The drug is no longer needed. Furthermore, the oral administration of the lactoferrin enteric preparation was continued, and an ophthalmologist was diagnosed in the second week. In addition, contact lenses that could not be worn for more than 30 years can be used again.
実施例3:
ドライアイと診断され、視力が左0.6,右0.5の55才女性が実施例1の錠剤を2カ月、毎日2錠内服した。1週間経過するとドライアイが著しく改善され、視力が左右とも1.0に回復した。3日頃から20年来悩まされてきた頭痛が消失した。頭痛はよく効くクスリがあったが、副作用が出て効力が弱いクスリに切り替えていたがほとんど効果がなかった。しかし、牛乳ラクトフェリンの腸溶錠を一日2錠内服すると頭痛が消失したので、現在、頭痛薬はのんでいない。また、昔からうつ病気味で、過呼吸症候群で二度ほど救急車を呼んで病院に運ばれた経験がある。7月3日に社交ダンスの会合があったが、昔ほど本番前の激しい動悸がしなくなった。ラクトフェリン内服1カ月後で血清中性脂肪が316mg/dlから85mg/dlへと大きく低下した。
Example 3:
A 55-year-old woman who was diagnosed with dry eye and had a visual acuity of 0.6 on the left and 0.5 on the right took 2 tablets of Example 1 every day for 2 months. After 1 week, dry eye was remarkably improved and visual acuity recovered to 1.0 on both the left and right sides. The headache that had been plagued for 20 years from around 3 days has disappeared. The headache had a meds that worked well, but switched to a less meds with side effects, but had little effect. However, since headache disappeared when two enteric lactoferrin enteric tablets were taken a day, no headache medicine is currently available. He also has a history of being depressed and having been taken to a hospital by calling an ambulance twice for hyperventilation syndrome. There was a social dance meeting on July 3rd, but it wasn't as intense as before. One month after oral administration of lactoferrin, serum triglyceride decreased greatly from 316 mg / dl to 85 mg / dl.
実施例4:
45才女性のドライアイが実施例1の錠剤を一日6錠7日間内服して著明に改善された。彼女は18才のときに検眼で近視(左0.5,右0.3)を指摘され、コンタクトレンズをはめるようになった。しかし、30才になってひどいドライアイで、コンタクトレンズがはめるときに痛みが走るようになった。ドライアイは次第に悪化し、40才になると常習性角膜上皮剥離のためコンタクトレンズの装着ができなくなった。眼球が乾燥して痛みがあるため、頻繁に瞬きしなければならず、目薬の携帯が必須となった。しかし、実施例1の錠剤を朝食と夕食直前に3錠ずつ内服したところ、1週間後からドライアイが改善し、目薬の点眼が不要になった。
Example 4:
A 45-year-old female, dry eye, took the tablet of Example 1 6 tablets a day for 7 days, which markedly improved. When she was 18 years old, she was pointed to myopia (left 0.5, right 0.3) by optometry and began to wear contact lenses. However, when I was 30 years old, I had a terrible dry eye, and my pain started running when the contact lenses were worn. Dry eyes gradually deteriorated, and at the age of 40, contact lenses could not be worn due to habitual corneal epithelial detachment. Eyeballs were dry and painful, so they had to blink frequently, and it was necessary to carry eye drops. However, when three tablets of Example 1 were taken immediately before breakfast and dinner, dry eye improved after one week, and eye drops were no longer required.
実施例5:
ドライアイのためにゴルフのスコアが低下していた男性(46才)の視力が実施例1の錠剤を一日3錠内服することにより大きく改善された。彼は三十歳台ではゴルフリンクを70台のスコアで回っていたが、四十才になるとドライアイのために視力が低下し、芝生のアンジュレーションが見えないので落とし所がわからず、パターを打つときには心臓がどきどきして失敗が多かった。2003年5月1日から実施例1の錠剤を一日3錠を毎食前に内服した。内服1週間目に気づいたもつとも大きな変化は、視力が回復してグリーンのアンジュレーションが再び見えるようになったことである。見えるようになってゴルフのスコアが大きく改善され、再び70台後半から80台のスコアが出るようになった。また、パターを打つときも、ビビラなくなったこともラクトフェリン腸溶製剤を内服し始めて起こった大きな変化である。
Example 5:
The visual acuity of a man (46 years old) whose golf score had decreased due to dry eye was greatly improved by taking the tablet of Example 1 three times a day. At the age of thirty, he played golf links with a score of 70, but when he was forty, his eyesight decreased due to dry eyes and he could n’t see the undulation of the lawn, so he did n’t know where it was going to go. There were many failures when I hit the heart. From May 1, 2003, 3 tablets per day of Example 1 were taken before each meal. The biggest change I noticed in the first week of internal use is that my eyesight has recovered and I can see the green undulation again. It became visible and the score of golf was greatly improved, and the score of 80 cars came out from the latter half of 70 cars again. Also, when putting a putter, it was a big change that happened when I started taking lactoferrin enteric preparations.
実施例6:
ドライアイと診断されていた53才の女性の視力が、実施例1の錠剤を一日6錠内服1カ月後に劇的に改善した。2003年4月19日ラクトフェリン錠を内服する直前の視力は、左0.6と右0.8だった。腸溶性ラクトフェリン錠剤(1錠中に牛乳から抽出したラクトフェリン100mg含有)を2錠ずつ10:00,15:00と20:00の一日三回、噛まずに内服したところ、5月24日の視力測定では左右とも視力は1.2に改善していた。この視力改善は、ドライアイが改善されたため頻繁にマバタキをしなくなった結果と思われる。
Example 6:
The visual acuity of a 53-year-old woman who had been diagnosed with dry eye dramatically improved the tablet of Example 1 six months a day after one month. The visual acuity just before taking the lactoferrin tablet on April 19, 2003 was 0.6 on the left and 0.8 on the right. Two tablets of enteric lactoferrin (containing 100 mg of lactoferrin extracted from milk in one tablet) were taken at 10:00, 15:00, and 20:00 three times a day without chewing. In the visual acuity measurement, the visual acuity improved to 1.2 on both the left and right sides. This improvement in visual acuity seems to be the result of the frequent loss of mabataki due to the improvement of dry eye.
Claims (1)
An enteric preparation for treatment or prevention of dry eye, habitual corneal epithelial detachment, or ocular disorder using contact lenses, comprising lactoferrin as an active ingredient.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008318445A JP5033115B2 (en) | 2008-12-15 | 2008-12-15 | Novel pharmaceutical composition and processed food for treating or preventing dry eye |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008318445A JP5033115B2 (en) | 2008-12-15 | 2008-12-15 | Novel pharmaceutical composition and processed food for treating or preventing dry eye |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003336468A Division JP4278473B2 (en) | 2003-08-22 | 2003-08-22 | Novel pharmaceutical composition for treating or preventing dry eye |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2009102353A JP2009102353A (en) | 2009-05-14 |
JP5033115B2 true JP5033115B2 (en) | 2012-09-26 |
Family
ID=40704461
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008318445A Expired - Fee Related JP5033115B2 (en) | 2008-12-15 | 2008-12-15 | Novel pharmaceutical composition and processed food for treating or preventing dry eye |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP5033115B2 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5899773B2 (en) * | 2011-10-05 | 2016-04-06 | 株式会社Nrlファーマ | Pharmaceutical composition for improving menopause and food and drink |
WO2014119629A1 (en) * | 2013-01-31 | 2014-08-07 | ライオン株式会社 | Composition, food or drink, visceral fat reducing agent and blood sugar level lowering agent |
KR20170134385A (en) * | 2015-04-08 | 2017-12-06 | 라이온 가부시키가이샤 | COMPRESSION AND METHOD FOR IMPROVEMENT OF DISINFORABILITY AND DECOMPATIBILITY |
JP6570112B2 (en) * | 2015-06-18 | 2019-09-04 | ジャパンモード株式会社 | Pharmaceutical manufacturing method |
WO2016174861A1 (en) * | 2015-04-27 | 2016-11-03 | ジャパンモード株式会社 | Oral care composition |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07316069A (en) * | 1994-05-24 | 1995-12-05 | Tokushu Meneki Kenkyusho:Kk | Composition for preventing and treating opportunistic infection |
JP4592041B2 (en) * | 2000-11-24 | 2010-12-01 | 株式会社Nrlファーマ | New food production methods and applications that improve quality of life |
-
2008
- 2008-12-15 JP JP2008318445A patent/JP5033115B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
JP2009102353A (en) | 2009-05-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Cronau et al. | Diagnosis and management of red eye in primary care | |
JP4278473B2 (en) | Novel pharmaceutical composition for treating or preventing dry eye | |
RU2589703C2 (en) | Use of omega fatty acids for treating disease | |
TWI406666B (en) | Niu Zhangzhi for the treatment of diseases | |
JP2002539173A (en) | Medications for treating diabetes | |
US20070225368A1 (en) | Therapy for Multiple Sclerosis | |
JP5033115B2 (en) | Novel pharmaceutical composition and processed food for treating or preventing dry eye | |
EP1572206B1 (en) | Compositions of non-steroidal anti-inflammatory drugs decongestants and anti-histamines | |
Flach | The importance of eyelid closure and nasolacrimal occlusion following the ocular instillation of topical glaucoma medications, and the need for the universal inclusion of one of these techniques in all patient treatments and clinical studies | |
Sodhi et al. | Subconjunctival hemorrhage: the first presenting clinical feature of idiopathic thrombocytopenic purpura | |
JP5106809B2 (en) | Pharmaceutical composition and processed food containing lactoferrin | |
WO2008122032A2 (en) | Treatment method for mmp-implicated pathologies | |
JP3183378B2 (en) | Mucin production promoter | |
CN109865016A (en) | A kind of pharmaceutical composition and its preparation method and application for treating xerophthalmia | |
KR20240027045A (en) | How to treat obstructive sleep apnea | |
Örnek et al. | Effect of 1% brinzolamide and 0.5% timolol fixed combination on intraocular pressure after cataract surgery with phacoemulsification | |
Moffat | Endolymphatic mastoid shunt surgery in unilateral Meniere's disease | |
KR102571939B1 (en) | A composition for improving dry eye syndrome comprising Tetraselmis chuii | |
Weaver et al. | Update: Do ophthalmic nonsteroidal anti-inflammatory drugs reduce the pain associated with simple corneal abrasion without delaying healing? | |
WO2022233318A1 (en) | Use of cistanche tubulosa extract in the preparation of a medicament for relieving dry eye syndrome | |
Kamaliya et al. | Central retinal vein occlusion and its management through Ayurveda: A case report | |
CN114831987A (en) | Eye drops and preparation method thereof | |
WO2003020274A1 (en) | Treatment of atopic dermatitis | |
JPH02292226A (en) | Agent for activating, preventing and treating disordered nerve cell | |
Seifert et al. | Drugs for the Treatment of Glaucoma and Age-Related Macular Degeneration |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20111004 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20111130 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20120214 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120424 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20120509 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20120626 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120629 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5033115 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150706 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |